Byannli (previously Paliperidone Janssen-Cilag International) Den Europæiske Union - dansk - EMA (European Medicines Agency)

byannli (previously paliperidone janssen-cilag international)

janssen-cilag international n.v.   - paliperidonpalmitat - skizofreni - psykoleptika - byannli (previously paliperidone janssen-cilag international) a 6 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly or 3 monthly paliperidone palmitate injectable products (see section 5.

Ionsys Den Europæiske Union - dansk - EMA (European Medicines Agency)

ionsys

janssen-cilag international nv - fentanylhydrochlorid - smerte, postoperative - analgetika - håndtering af akutte moderat til svær post-operative smerter til brug på et hospital indstilling kun.

Regranex Den Europæiske Union - dansk - EMA (European Medicines Agency)

regranex

janssen-cilag international nv - becaplermin - wound healing; skin ulcer - præparater til behandling af sår og sår - regranex angives i forening med andre gode sår pleje foranstaltninger, at fremme granulering og dermed heling af fuld-tykkelse, neuropatiske, kronisk, diabetisk sår mindre end eller lig til 5 cm2.

Doribax Den Europæiske Union - dansk - EMA (European Medicines Agency)

doribax

janssen-cilag international nv - doripenem - pneumonia, ventilator-associated; pneumonia, bacterial; urinary tract infections; bacterial infections; cross infection - antibakterielle midler til systemisk brug, - doribax er indiceret til behandling af følgende infektioner hos voksne:nosokomiel pneumoni (herunder ventilator-associeret pneumoni);kompliceret, intra-abdominale infektioner;komplicerede urinvejsinfektioner. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..

Rekambys Den Europæiske Union - dansk - EMA (European Medicines Agency)

rekambys

janssen-cilag international nv - rilpivirine - hiv infektioner - antivirale midler til systemisk anvendelse - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.

Imbruvica Den Europæiske Union - dansk - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.